Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT02991469Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Aug 2018
- Primary completion
- Mar 2028
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 2 trial of sarilumab in systemic juvenile idiopathic arthritis (SJIA), sponsored by Sanofi. Started Aug 2018; status: recruiting.
02
Drugs
sarilumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NCT02991469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02991469.